Abstract
A series of novel Schiff bases -benzothiazole hybrids was designed, synthesized and evaluated for their anticancer activity by MTT assay and western blot method. Antiproliferative screening indicated that compound containing dihydroxy substituents had potent inhibitory activity with IC50 value 34µg/ml against SKOV3, A2780-S and A2780-CR cell lines. It showed more potent cytotoxicity in combination with cisplatin and paclitaxel than alone in the selected cell lines (SKOV3, A2780 and A2780-CR models). The in vitro cytotoxicity of the compounds on IOSE 364 cell line was evaluated to establish the selectivity. Molecular docking study exhibited good binding against epidermal growth factor receptor, which was further ascertained by immunoblot assay using specific antibody against phosphorylated EGFR, and thus unravelling the targeted anticancer mechanism.
Keywords: A2780-CR, A2780-PR, A2780-S, benzothiazole, schiff bases, SKOV3.
Graphical Abstract
Anti-Cancer Agents in Medicinal Chemistry
Title:Design and Synthesis of Novel Schiff Base-Benzothiazole Hybrids as Potential Epidermal Growth Factor Receptor (EGFR) Inhibitors
Volume: 16 Issue: 6
Author(s): Meenakshi Singh, Sudhir Kumar Singh, Bhushan Thakur, Pritha Ray and Sushil K. Singh
Affiliation:
Keywords: A2780-CR, A2780-PR, A2780-S, benzothiazole, schiff bases, SKOV3.
Abstract: A series of novel Schiff bases -benzothiazole hybrids was designed, synthesized and evaluated for their anticancer activity by MTT assay and western blot method. Antiproliferative screening indicated that compound containing dihydroxy substituents had potent inhibitory activity with IC50 value 34µg/ml against SKOV3, A2780-S and A2780-CR cell lines. It showed more potent cytotoxicity in combination with cisplatin and paclitaxel than alone in the selected cell lines (SKOV3, A2780 and A2780-CR models). The in vitro cytotoxicity of the compounds on IOSE 364 cell line was evaluated to establish the selectivity. Molecular docking study exhibited good binding against epidermal growth factor receptor, which was further ascertained by immunoblot assay using specific antibody against phosphorylated EGFR, and thus unravelling the targeted anticancer mechanism.
Export Options
About this article
Cite this article as:
Singh Meenakshi, Singh Kumar Sudhir, Thakur Bhushan, Ray Pritha and Singh K. Sushil, Design and Synthesis of Novel Schiff Base-Benzothiazole Hybrids as Potential Epidermal Growth Factor Receptor (EGFR) Inhibitors, Anti-Cancer Agents in Medicinal Chemistry 2016; 16 (6) . https://dx.doi.org/10.2174/1871520615666151007160115
DOI https://dx.doi.org/10.2174/1871520615666151007160115 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
LncRNA HOTAIR Polymorphisms Association with Cancer Susceptibility in Different Tumor Types
Current Drug Targets Are KRAS/BRAF Mutations Potent Prognostic and/or Predictive Biomarkers in Colorectal Cancers?
Anti-Cancer Agents in Medicinal Chemistry Biosurfactants as a Novel Additive in Pharmaceutical Formulations: Current Trends and Future Implications
Current Drug Metabolism The Emerging Role of Unmetabolized Folic Acid in Human Diseases: Myth or Reality?
Current Drug Metabolism Adhesion Molecules as Targets for the Treatment of Neoplastic Diseases
Current Pharmaceutical Design Therapeutic Potential of Host Defense Peptides in Antibiotic-resistant Infections
Current Pharmaceutical Design Synthesis and Anti-Cancer Activities of Aryl Benzyl Ethers with Fluoro Substituents
Letters in Drug Design & Discovery Clinical Impact of the Detection of BRAF Mutations in Thyroid Pathology: Potential Usefulness as Diagnostic, Prognostic and Theragnostic Applications
Current Medicinal Chemistry Targeting the Ubiquitin-Proteasome Pathway: An Emerging Concept in Cancer Therapy
Current Topics in Medicinal Chemistry The Applications of Biomarkers in Early Clinical Drug Development to Improve Decision-Making Processes
Current Clinical Pharmacology IDO+ DCs and Signalling Pathways
Current Cancer Drug Targets Activated Cancer Therapy Using Light and Ultrasound - A Case Series of Sonodynamic Photodynamic Therapy in 115 Patients Over a 4 Year Period
Current Drug Therapy Chemical & RNAi Screening at MSKCC: A Collaborative Platform to Discover & Repurpose Drugs to Fight Disease
Combinatorial Chemistry & High Throughput Screening EGFR-Targeting Monoclonal Antibodies in Head and Neck Cancer
Current Cancer Drug Targets 2-Aminoimidazole, Glycociamidine and 2-Thiohydantoin-Marine Alkaloids as Molecular Inspirations for the Development of Lead Structures
Current Drug Targets Poxvirus Cancer Therapy
Recent Patents on Anti-Infective Drug Discovery Mapping the High Throughput SEREX Technology Screening for Novel Tumor Antigens
Combinatorial Chemistry & High Throughput Screening Survivin as a Prognostic/Predictive Marker and Molecular Target in Cancer Therapy
Current Medicinal Chemistry Quantitative Analysis and Pharmacokinetics Study of Integrin Antagonist AP25 in Rat Plasma
Protein & Peptide Letters Hsp90 Inhibition with Resorcylic Acid Lactones (RALs)
Current Topics in Medicinal Chemistry